Clinical Trials Logo

Filter by:
NCT ID: NCT05724732 Recruiting - Solid Tumor Clinical Trials

Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors

Start date: February 1, 2023
Phase: Early Phase 1
Study type: Interventional

This study is a single-center, single-arm phase I clinical trial. A total of 24~26 subjects (20 evaluable cases are expected) from 1 cohort will be enrolled in this study. An "autologous tumor-infiltrating lymphocyte therapy" dosing regimen consisting of lymphodepleting chemotherapy (FC regimen: cyclophosphamide + fludarabine), infusion of autologous tumor-infiltrating lymphocyte injection, and interleukin-2 injection will be used.The study process is divided into: screening period, sampling and production period, clearing and chemotherapy period, treatment and observation period, and follow-up period

NCT ID: NCT05724355 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice.

NCT ID: NCT05724342 Recruiting - Stroke, Ischemic Clinical Trials

Tenecteplase REperfusion in Acute Ischemic sTroke Registry(TREAT)

Start date: February 15, 2023
Phase:
Study type: Observational

The aim of the study was to establish tenecteplase thrombolysis database and to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients.

NCT ID: NCT05724329 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinomas

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Start date: February 5, 2023
Phase: Phase 2
Study type: Interventional

The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in combination with dasatinib and quercetin(combining immunotherapy and senolytics, COIS) in patients with head and neck squamous cell carcinoma who are about to undergo surgery.

NCT ID: NCT05723991 Recruiting - Clinical trials for Urothelial Carcinoma

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Start date: September 28, 2022
Phase: Phase 4
Study type: Interventional

A multicenter, open, single arm, phase II clinical trial was designed for myometrial invasive bladder cancer to evaluate the efficacy and safety of RC48-ADC combined with gemcitabine in preoperative neoadjuvant treatment of MIBC, and provide high-level clinical evidence for gemcitabine combined with ADC in the treatment of MIBC

NCT ID: NCT05723731 Recruiting - Clinical trials for Chronic Constipation

Effect of Transcutaneous Auricular Vagal Nerve Stimulation on Chronic Constipation

Start date: January 3, 2023
Phase: N/A
Study type: Interventional

The worldwide prevalence of chronic constipation (CC) is 15%, and women are more likely to develop the disease than men. CC have a significant impact on quality of life and increase the burden of national health insurance. The conventional medication treatments are primarily symptom-specific and have limited efficacy. Previous small sample study had shown the therapeutic potential of transcutaneous auricular vagus nerve stimulation (taVNS) for irritable bowel syndrome with constipation (IBS-C). The aim of this study was to investigate whether taVNS could improve defecation condition and constipation symptoms in patients with CC.

NCT ID: NCT05723432 Recruiting - Melanoma Clinical Trials

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Start date: March 22, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with toripalimab in patients with advanced melanoma.

NCT ID: NCT05723263 Recruiting - Gonorrhea Clinical Trials

Pay-it-forward Gonorrhea and Chlamydia Testing Among Men in China

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

PIONEER is a three-arm, programmatic cluster randomized controlled trial (RCT) to compare effectiveness of three implementation strategies, followed by a mixed-methods implementation evaluation study

NCT ID: NCT05723003 Recruiting - Pulmonary Embolism Clinical Trials

Prospective Validation of an Acute Pulmonary Embolism Severity and Prognosis Prediction Model

Start date: February 1, 2023
Phase:
Study type: Observational

The purpose of this study is to prospectively validate the first PUMCH model for acute PE severity and prognosis prediction based on multi-center data constructed in the pre-project period based on national population data, and to optimize the PUMCH model based on artificial intelligence clustering algorithm.

NCT ID: NCT05722964 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis

Start date: March 29, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of intravenous SHR-1906 in the treatment of idiopathic pulmonary fibrosis. The study is divided into four stages: screening period, baseline period, treatment period and safe follow-up period. It is planned that 108 patients will be randomly assigned to the following three treatment groups for treatment